Hemab Therapeutics Holdings, Inc.
corporate_fare Company Profile
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) is a publicly traded company in the Life Sciences sector. Wiseek monitors COAG SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Hemab Therapeutics Reports Q1 Net Loss of $(22.7)M, EPS $(23.98) Post-IPO
- Hemab Therapeutics Reports Q1 Loss, Confirms Cash Runway into 2029 Post-IPO
- Hemab Therapeutics Secures Cash Runway into 2029, Gains Breakthrough Therapy Designation for Lead Candidate
- Access Industries and Len Blavatnik Disclose 10.4% Stake in Hemab Therapeutics Post-IPO
- RA Capital, a 10% Owner and Director, Makes Substantial $172M Post-IPO Investment in Hemab Therapeutics
Dilution Risk
Low riskFiling-implied dilution signals for COAG, detected from its recent SEC filings · latest filing 2026-05-01.
Initial Public Offering Completed · Substantial Capital Raise
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →